ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

ClinicalTrials.gov ID: NCT02677896

Public ClinicalTrials.gov record NCT02677896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Study identification

NCT ID
NCT02677896
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Enrollment
1,150 participants

Conditions and interventions

Interventions

  • Enzalutamide Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 8, 2016
Primary completion
Oct 13, 2018
Completion
Jul 30, 2024
Last update posted
Oct 23, 2025

2016 – 2024

United States locations

U.S. sites
34
U.S. states
23
U.S. cities
33
Facility City State ZIP Site status
Site US10016 Homewood Alabama 35209
Site US10007 Anchorage Alaska 99503
Site US10008 Tucson Arizona 85741
Site US10034 Fountain Valley California 92708
Site US10056 La Jolla California 92093
Site US10026 Santa Rosa California 95403
Site US10035 Aurora Colorado 80045
Site US10050 Denver Colorado 80220
Site US10048 St. Petersburg Florida 33710
Site US10054 Thomasville Georgia 31792
Site US10015 Chicago Illinois 60637
Site US10043 Springfield Illinois 62703
Site US10045 Jeffersonville Indiana 47130
Site US10020 West Des Moines Iowa 50266
Site US10055 Kansas City Kansas 66160-7233
Site US10017 Towson Maryland 21204
Site US10036 Omaha Nebraska 68114
Site US10018 Lawrenceville New Jersey 08648
Site US10025 Newburgh New York 12550
Site US10029 Syracuse New York 13210
Site US10068 Charlotte North Carolina 28207
Site US10009 Concord North Carolina 28025
Site US10014 Durham North Carolina 27710
Site US10060 Greenville North Carolina 27834
Site US10044 Middleburg Heights Ohio 44130
Site US10011 Lancaster Pennsylvania 17604
Site US10012 Myrtle Beach South Carolina 29572
Site US10059 Nashville Tennessee 37208
Site US10046 Dallas Texas 75231
Site US10004 Dallas Texas 75390-9110
Site US10040 Virginia Beach Virginia 23462
Site US10002 Burien Washington 98166
Site US10013 Seattle Washington 98101
Site US10028 Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02677896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 23, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02677896 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →